Randomised controlled trial of the tolerability and completion of Maraviroc compared to Kaletra; in combination with Truvada; for HIV Post Exposure Prophylaxis.
Phase of Trial: Phase IV
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
- Indications HIV infections
- Focus Adverse reactions
- Acronyms MiPEP
- Sponsors Pfizer
- 20 Mar 2017 Results published in the Journal of Antimicrobial Chemotherapy
- 19 Feb 2015 Planned End Date changed from 31 Jan 2015 to 31 Dec 2014 as per United Kingdom Clinical Research Network record.
- 04 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.